Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has reaffirmed a Buy rating on Myriad Genetics (NASDAQ:MYGN) and increased the price target from $28 to $31.
January 30, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Myriad Genetics and raises the price target to $31, indicating a positive outlook on the stock.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals confidence in the company's future performance and can lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100